General Session 5: Novel and Systemic Therapies

Chairs: Ann-Lii Cheng, MD, PhD (Taiwan) and Andrew X. Zhu, PhD (USA)

  • O-029 Phase 2 Study of the Oral Transforming Growth Factor-Beta (Tgf- B) Receptor I Kinase Inhibitor Ly2157299
    G. Giannelli, A. Santoro, R. K. Kelley, P. Merle, E. Gane, J.-Y. Douillard, D. Waldschmidt, M. Mulcahy, C. Costentin, G. Lorusso, I. Gueorguieva, A. Cleverly, D. Desaiah, M. M. Lahn, N.Murray, K. A. Benhadji, E. Raymond, S. Faivre

  • O-030 Tolerability and Safety Data in Patients with Hepatocellular Carcinoma who Received Multiple Intratumoral and/or Intravenous Treatments of Pexa-Vec (Jx-594) In Two Phase 2 Studies
    C. Breitbach, J. Heo, M. Cho, T. Reid, H. Y. Lim, C. W. Kim, L. Ruo, M. Bloomston, H. C. Chung, R. Patt, R. Lencioni, T.-H. Hwang, J. Burke

  • O-031 Updated Results from Phase1/2 Trial of Lenvatinib (E7080), A Multi-Targeted Tyrosine Kinase Inhibitor, and Biomarker Correlative Analyses in Patients (Pts) with Advanced Hepatocellular Carcinoma (HCC)
    M. Kudo, H. Kumada, K. Ikeda, S. Kawazoe, Y. Osaki, M. Ikeda, T. Okusaka, T. Tamai, T. Suzuki, T. Kadowaki, Y. Funahashi, J. P.O’Brien, K. Okita

  • O-032 Resminostat in Advanced Hepatocellular Carcinoma (HCC): Overall Survival Subgroup Analysis of Prognostic Factors in the Shelter Trial
    M. Bitzer, T. M. Ganten, H. Wege, E. G. Giannini, F. Trevisani, B. Hauns, A. Mais, J. Asche, T. Herz, S. Pegoraro, A. Ammendola S. W. Henning, B. Hentsch

  • O-034 A Multicenter, Single-Arm, Phase 2 Study Evaluating Cixutumumab in Combination with Sorafenib as First-Line Systemic Therapy for Patients with Advanced Hepatocellular Carcinoma
    K. Stuart, M. Borad, S. Sadeghi, M. Mulcahy, J. Gurtler, W. Sun, R. Willey, J. Cosaert, A. Siegel